4055 41st Avenue South
33 articles with Aldevron
A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease.
Ginkgo has signed multiple collaborations, announced a breakthrough in manufacturing mRNA vaccine components, and landed an SPAC deal.
Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines
Aldevron and Ginkgo Bioworks , Inc. ("Ginkgo") today announced a manufacturing breakthrough driven by their strategic partnership.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
Danaher Corporation (NYSE: DHR) (the "Company") announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion.
Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products
Aruvant Sciences and Aldevron announced that Aldevron will support the development of ARU-1801, Aruvant's one-time investigational gene therapy for sickle cell disease, and ARU-2801, a one-time investigational gene therapy for hypophosphatasia.
Aldevron, the world’s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced the addition of three reporter Self-amplifying RNA products to its growing catalog: AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™.
Aldevron the First to Rapidly Discover Human Antibodies Using Ligand's OmniRat® Platform and Berkeley Lights' Beacon® Instrument
Aldevron the First to Rapidly Discover Human Antibodies Using Ligand's OmniRat ® Platform and Berkeley Lights' Beacon ® Instrument
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Cynthia Biffert as Vice President of its GMP Nucleic Acids Business Unit (NABU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005378/en/ Cynthia Biffert, Vice President of Aldevron's GMP Nucleic Acids Business Unit (Photo: Business Wire) Biff
Aldevron Announces Agreement with Ziopharm Oncology for neoGMP® Production of Sleeping Beauty Plasmid DNA to Express TCRs for Treatment of Solid Tumors
Aldevron, a leading provider of products and services for the biotechnology industry, today announced an agreement with Ziopharm Oncology to produce plasmid DNA for T cell therapy of solid tumors.
Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President of its Research Grade nucleic acids business unit.
Feb. 18, 2020 14:30 UTC FARGO, N.D.--( BUSINESS WIRE )-- Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218
Phase one of the construction project will start in August. Once completed, its annual capacity will be more than $1 billion of plasmid DNA, RNA, gene editing enzymes and other biologics.
Increasing GENOVAC platform capacity and antibody development services necessary to meet demand
New plasmid to reduce cost and timeline for gene therapy manufacturing.
Aldevron and DNA Technologies. Inc. announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFi Cas9 Nuclease—which is patented by IDT.